Adept Biopharma develops innovative immuno-therapeutics to help cancer patients.
Adept Biopharma develops innovative immuno-therapeutics to help cancer patients. Adept Biopharma has mastered the world's leading antibody discovery technology, has a unique NKCE bispecific antibody platform and an ABCC antibody/chemo/cytokine (receptor) trispecific antibody platform, and can also obtain fully human antibodies through external cooperation.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Jan 1, 2021 | Angel | — | 1 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
BIOCHING CAPITAL | — | Angel |